Zusammenfassung
Es wird ein adjuvantes Therapiekonzept mit Interferon-alpha und Interleukin-2 bei Patienten mit „High Risk“ malignen Melanom vorgestellt. Die induzierte Immunaktivität, dokumentiert durch den IL-2-Rezeptor-Anstieg im Serum, könnte einen möglichen Therapieerfolg bei vergleichsweise geringen Nebenwirkungen erklären.
Summary
The authors describe the immunotherapy using alpha-interferon and interleukin-2 in patients with “High Risk“ malignant melanoma. The induced activity of the immune system, documented by the elevation of the IL-2-receptor-serum-level, could explane possible therapeutic aspects in patients. During therapy only mild toxicity has been observed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Chen BD, Najor F (1987) Macrophage activation by interferon a + B is associated with a loss of proliferative capacity: Role of interferon a+B in the regulation of macrophage proliferation and function. Cell Immunol 106: 343–354
Fidler I J, Heicappell R, Saiki I (1987) Direct antiproliferative effects of recombinant human interferon-a. B/D hybrids on human tumor cell lines. Cancer Res 47: 2020–2027
Hicks NJ, Morris AG, Burke DC (1981) Partial reversion of the transformed Phenotype of murine sarcoma virustransformed cells in the presence of interferon: A possible mechanims for the antitumor effects of interferon. J Cell Sci 49: 225–236
Knop J, Taborski B, DeMaeyer-Guignard J (1987) Selective inhibition of the generation of T suppressor cells of contact sensitivity in vitro by interferon. J Immunol 138: 3684–3687
Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA (1986) High dose recombinant interleukin-2 in the treatment of patients with dissemenated cancer: Responses, treatment related morbidity and histologic findings. JAMA 256: 3117–3124
Rosenberg SA (1988) Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells, in DeVita V, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, PA, Lippin cott, pp 217–257
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 889–905
Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, White DE (1989) Combination Therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin One, Vol 7: 1863–1874
Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL (1985) Soluble Interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135: 3172–3177
Stotter H, Rude E, Wagner H (1980) T cell factor (interleukin-2) allows in vivo induction of T helper cells against heterologous erythrocytes in nude (nu/nu) mice. Eur J Immunol 10: 719
Talmadge JE, Herberman RB, Chirigos MA (1985) Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators including recombinant interferons and interleukin-2. J Immunol 135: 2483–2488
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Schultz, E.S., Dummer, R., Müller, W., Hartmann, A.A., Burg, G. (1992). Immunmodulation mit Interferon-alpha und Interleukin-2 beim malignen Melanom. In: Burg, G., Hartmann, A.A., Konz, B. (eds) Onkologische Dermatologie. Fortschritte der operativen und onkologischen Dermatologie, vol 7. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77690-8_24
Download citation
DOI: https://doi.org/10.1007/978-3-642-77690-8_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-77691-5
Online ISBN: 978-3-642-77690-8
eBook Packages: Springer Book Archive